Evercore ISI lowers McKesson stock price target to $950 on growth concerns

Evercore ISI cut McKesson's price target to $950 from $1,000 and added the stock to its TAP tactical outperform list; shares trade at $868 versus an InvestingPro Fair Value of $935 (PEG 0.41). Evercore expects Q4 FY26 results slightly below Street and forecasts ~9% adjusted operating income growth in North America Pharma and ~14% in Oncology & Medical, while warning slower growth in Prescription Technology Solutions due to cash-pay GLP‑1; FY26 includes one-time benefits of ~$70m (Norway), ~$51m (Oncology gains) and ~$15m (venture) that should be excluded from forward projections. Other analyst moves: BofA trimmed targets (noted at $1,000 and also a $970 reiteration) but kept Buy, Argus raised its PT to $1,050, and Leerink/Evercore reiterated Outperform with PTs of $1,085 and $1,000; McKesson is also executing a CFO transition (Britt Vitalone retiring, Kenny Cheung to assume role in May 2026).

Analysis

McKesson’s recent narrative pivot—reinvesting proceeds into higher-growth channels while shrinking non-core footprints—creates an asymmetric outcome: operating leverage remains intact in stable distribution flows while software/tech revenue becomes the main variable. The key second-order effect is that persistent cash-pay prescription behavior not only reduces claim volumes but also alters marginal pricing power for transaction-based tech fees, compressing revenue per claim even if prescription counts stabilize.

This dynamic transfers growth optionality from predictable volume capture to execution on higher-growth verticals (oncology, specialty logistics) and M&A redeployments; those are multi-quarter to multi-year plays where execution and transitional costs matter more than quarterly beats. Governance continuity through a phased finance leadership handoff lowers short-term execution shock, but creates a 6–18 month window where market attention will be on margin cadence and disposal proceeds reinvestment—exact timing is the primary catalyst.

Tail risks are structural (cash-pay persistence becoming dominant in certain therapeutic classes), regulatory (changes to reimbursement or data access for tech offerings), and competitive (peers or vertical SaaS entrants undercutting take-rates). A reversal could come quickly if payors reintroduce rebates or reimbursement pathways for cash-pay therapies, which would restore transactional economics for middleware players within 2–4 quarters. For portfolio construction, this is a stock where idiosyncratic execution bets and event-timed optionality dominate sector beta, suggesting trades that isolate company-level outcomes rather than broad healthcare exposure.

Key Decisions for Investors

• Directional, idiosyncratic long (MCK) — Buy a 12–24 month LEAP call with ~0.30–0.40 delta to play execution on higher-growth verticals while limiting premium outlay; finance by selling a further OTM call (calendar or vertical) to improve carry. Reward: upside to successful redeployment/M&A; Risk: tech-segment secular downside and transient margin hits. Timeframe: 12–24 months.
• Pair trade to isolate distribution vs tech risk — Go long MCK equity and short AmerisourceBergen (ABC) equal notional for 6–12 months to express confidence in company-specific execution (asset redeployment, oncology/logistics) while neutralizing sector-wide pharma distribution cyclicality. Reward: outperformance if redeployment and margin initiatives succeed; Risk: sector shock or supply-chain event that impacts both.
• Short concentrated tech-exposure via options — Buy a 6–12 month put spread on MCK’s prescription-technology sensitivity (buy 0.30-delta puts, sell 0.15-delta lower strikes) sized to 20–30% of core long exposure to hedge cash-pay continuation risk. Reward: limited-cost protection against structural decline in transactional economics; Risk: premium loss if cash-pay reverts.
• Event-driven buy-write around divestiture milestones — Acquire shares and sell 9–12 month covered calls struck above a conservative upside threshold to harvest carry while preserving upside through announced separation/transaction windows. Reward: improves yield during multi-quarter execution window; Risk: missing larger upside in a deal-led rerating.